Cancer News and Research

Latest Cancer News and Research

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Treating non-osteoporotic compression fractures in patients with multiple myeloma, a blood cancer, shows that the use of vertebroplasty-a minimally invasive treatment performed by interventional radiologists using imaging guidance that stabilizes collapsed vertebrae with the injection of medical-grade bone cement into the spine-results in a reduction of pain, medication usage and disability, according to researchers in the largest study of its kind at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

President delivers emotional speech, pushes for reform in Ohio

The Associated Press: "With a fresh sense of urgency, President Barack Obama sought to reassure seniors Monday about health care legislation approaching a final vote in Congress, pledging it would make preventive care cost-free and close a gap in Medicare prescription drug coverage. 'This proposal adds almost a decade of solvency to Medicare,' Obama said in a visit to a senior center."

16 Mar 2010

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

16 Mar 2010

Research reveals molecular mechanism of DNA repair

New research led by scientists at the University of Essex has given an insight into how the body finds damage in the DNA code to repair it.

16 Mar 2010

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Anapol Schwartz attorneys Lawrence Cohan and Melissa Fry Hague recently filed two Gardasil vaccine complaints – one on behalf of a Kensington, Calif., family, whose 15-year old daughter died after suffering from severe adverse reactions, and another on behalf of a 19-year old Lapeer, Mich., woman, who has a chronic, autoimmune disorder. The cases, filed in The Court of Federal Claims in Washington, D.C., seek recovery under the National Vaccine Injury Compensation Program.

15 Mar 2010

Vertebroplasty: Patient selection vital

Patient selection is key for vertebroplasty—a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy—to be effective and successful, according to a study of more than 1,500 persons who were followed over seven years. Additionally, collaboration between an interventional radiologist and other medical experts in treating a patient is imperative, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

High ABI may indicate risk for future heart attacks

The prevalence of abnormal ankle-brachial index (ABI) test results among individuals tested for peripheral arterial disease (PAD)—and who are not considered at high risk of a coronary heart event by Framingham-based risk factors—is high and provides another way to identify those who may be at risk for future heart attacks, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

MannKind receives FDA Complete Response letter for AFREZZA NDA

MannKind Corporation today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia.

15 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

Novo Growth Equity invests in Orexo

Orexo AB and Novo A/S today announced combined transactions encompassing a directed new issue by Orexo of a SEK 111 million convertible bond to Denmark-based Novo A/S and the acquisition of significant blocks of existing shares by Novo A/S from two existing venture capital shareholders, subject to approval at an Extraordinary General Meeting. The conversion price of the convertible bonds is set at 25 per cent premium to the closing share price on 12 March, 2010.

15 Mar 2010

Cephalon Australia granted exclusive license to develop Innate Immune's antibodies for treatment of asthma, SLE

Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).

15 Mar 2010

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Enzo Biochem, Inc. today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

15 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

StockPreacher.com announces investment report featuring GenVec

StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Gene defects could become targets for new personalised treatments for bowel cancer

President delivers emotional speech, pushes for reform in Ohio

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Research reveals molecular mechanism of DNA repair

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Vertebroplasty: Patient selection vital

High ABI may indicate risk for future heart attacks

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

MannKind receives FDA Complete Response letter for AFREZZA NDA

CytRx plans five Phase 2 clinical trials with oncology drug candidates

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

Novo Growth Equity invests in Orexo

Cephalon Australia granted exclusive license to develop Innate Immune's antibodies for treatment of asthma, SLE

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

StockPreacher.com announces investment report featuring GenVec

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in